Magnesium carbonate 500mg capsules
Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label].
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Magnesium carbonate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Magnesium carbonate
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Magnesium carbonate
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(4)
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Chronic kidney disease: assessment and management (NG203)
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · Randomised trials: 2 · 1988–2026
Showing the 50 most relevant studies, sorted by most relevant.
S. Son, T. Gao, S. Harvey, et al.
Nature Chemistry, 2018
Boers JRM, Garcia M, Sanchez E, et al.
2026
- Calcium Carbonate
- Oxytocin
- Oxytocics
C. Unluer, A. Al-Tabbaa
Cement and Concrete Research, 2013
Zhiping Zhang, Yajun Zheng, Yu-wen Ni, et al.
The journal of physical chemistry. B, 2006
Ioannis P. Tzanakis, A. Papadaki, Mingxin Wei, et al.
International Urology and Nephrology, 2008
L. Mo, Yu Hao, Yunpeng Liu, et al.
Cement and Concrete Research, 2019
A. Botha, C.A. Strydom
Hydrometallurgy, 2001
I. Gibson, W. Bonfield
Journal of Materials Science: Materials in Medicine, 2002
Nailia Rakhimova
Construction and Building Materials, 2022
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
69 found
Half-life
27.7 hours
Mechanism
Magnesium carbonate reacts with hydrochloric acid in the stomach to form carbon…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
40-60%
[L593]
Percent absorption decreases as dose increases.
Half-life
27.7 hours
[L593]
Protein binding
30%
[L593]
Volume of distribution
0.2-0.4L/kg
[L593]
About 50% distributes to bone.
Metabolism
[L593]
Elimination
[L593]
Clearance
[L593]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L593]
It is also used in combination with [Citric acid] and [Gluconolactone] for use within the lower urinary tract in the dissolution of bladder calculi.
[L52555]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1301 interactions
[L593]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L593]
Percent absorption decreases as dose increases.
[L593]
[L593]
[L593]
About 50% distributes to bone.
[L593]
[L593]
[L593]
Proteins and enzymes this drug interacts with in the body
GluN3B subunit also binds D-serine and, in the absence of glycine, activates glycinergic receptor complexes, but with lower efficacy than glycine (By similarity). Each GluN3 subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, Ca2(+) permeability, and binding to allosteric modulators (By similarity)
Proteins that transport this drug across cell membranes
PMID:14576148 PMID:16636202 PMID:18258429 PMID:18365021
Crucial for Mg(2+) homeostasis. Has an important role in epithelial Mg(2+) transport and in the active Mg(2+) absorption in the gut and kidney .
PMID:14576148
However, whether TRPM6 forms functional homomeric channels by itself or functions primarily as a subunit of heteromeric TRPM6-TRPM7 channels, is still under debate PMID:14576148 PMID:16636202 PMID:24385424
PMID:11385574 PMID:12887921 PMID:15485879 PMID:24316671 PMID:35561741 PMID:36027648
Controls a wide range of biological processes such as Ca2(+), Mg(2+) and Zn(2+) homeostasis, vesicular Zn(2+) release channel and intracellular Ca(2+) signaling, embryonic development, immune responses, cell motility, proliferation and differentiation (By similarity). The C-terminal alpha-kinase domain autophosphorylates cytoplasmic residues of TRPM7 .
PMID:18365021
In vivo, TRPM7 phosphorylates SMAD2, suggesting that TRPM7 kinase may play a role in activating SMAD signaling pathways.
In vitro, TRPM7 kinase phosphorylates ANXA1 (annexin A1), myosin II isoforms and a variety of proteins with diverse cellular functions PMID:15485879 PMID:18394644
ATC A02AA01
ATC V03AE04
ATC A06AD01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Magnesium carbonate
Additional database identifiers
Drugs Product Database (DPD)
6880
Drugs Product Database (DPD)
703
Drugs Product Database (DPD)
6487
ChemSpider
10563
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4584
GenAtlas
GRIN1
GeneCards
GRIN1
GenBank Gene Database
D13515
GenBank Protein Database
219920
Guide to Pharmacology
455
UniProt Accession
NMDZ1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4585
GenAtlas
GRIN2A
GeneCards
GRIN2A
GenBank Gene Database
U09002
GenBank Protein Database
558749
Guide to Pharmacology
456
UniProt Accession
NMDE1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4586
GenAtlas
GRIN2B
GeneCards
GRIN2B
GenBank Gene Database
U90278
GenBank Protein Database
1899202
Guide to Pharmacology
457
UniProt Accession
NMDE2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4587
GenAtlas
GRIN2C
GeneCards
GRIN2C
GenBank Gene Database
L76224
GenBank Protein Database
1196449
Guide to Pharmacology
458
UniProt Accession
NMDE3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4588
GenAtlas
GRIN2D
GeneCards
GRIN2D
GenBank Gene Database
U77783
GenBank Protein Database
2444026
UniProt Accession
NMDE4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:16767
GenAtlas
GRIN3A
GeneCards
GRIN3A
GenBank Gene Database
AJ416950
GenBank Protein Database
20372905
UniProt Accession
NMD3A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:16768
GenAtlas
GRIN3B
GeneCards
GRIN3B
GenBank Gene Database
AC004528
GenBank Protein Database
3025446
UniProt Accession
NMD3B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:17995
GeneCards
TRPM6
Guide to Pharmacology
498
UniProt Accession
TRPM6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:31046
GeneCards
SLC41A3
UniProt Accession
S41A3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:103
GeneCards
CNNM2
UniProt Accession
CNNM2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:17994
GeneCards
TRPM7
Guide to Pharmacology
499
UniProt Accession
TRPM7_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72